Stock Movers: Jetblue, Humana, Solar Stocks
On this episode of Stock Movers: - JetBlue (JBLU) plans to hasten cost cuts by eliminating some flights, ending service to a number of cities and restructuring its leadership ranks as economic uncertainty feeds weaker-than-expected demand for travel, the company said in an internal memo. The carrier will eliminate underperforming routes and plans to announce network changes in coming weeks, according to the memo from Chief Executive Officer Joanna Geraghty seen by Bloomberg on Tuesday. JetBlue implemented budget reductions at support centers and is assessing hiring, spending on business partners and vendors and will combine or restructure some leadership roles. The carrier has halted cosmetic refreshes of four out of its 10 legacy Airbus A320 aircraft used for flights and will park the planes at the end of summer. 'We're hopeful demand and bookings will rebound, but even a recovery won't fully offset the ground we've lost this year and our path back to profitability will take longer than we'd hoped,' Geraghty said. 'That means we're still relying on borrowed cash to keep the airline running.' - Humana (HUM) shares were up as much as 4%, the most intraday in a month, as analysts are positive on the health insurer following its investor day event where it gave updates regarding expectations for earnings growth through 2028. KeyBanc Capital Markets says the investor day provided 'a clear picture' of the earnings power of the business and how the company plans to unlock margins by 2028. - Solar stocks, like Sunrun (RUN), SolarEdge (SEDG) and Enphase (ENPH) fell sharply after Senate Republicans released a bill that would end clean energy tax credits earlier than expected, dashing hopes that major cuts passed by the House wouldn't stick. The new version of the bill released by the Senate Finance Committee would end incentives for wind and solar in 2028. Tax breaks for other sources of power, such as nuclear, hydropower and geothermal, would be allowed to remain until being phased out in 2036, according to a summary of the legislation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Why KULR Technology Stock Is Plummeting Today
After the market closed last Friday, KULR announced that it will carry out a reverse stock split. KULR will implement an 8-for-1 reverse stock split on June 23. The reverse split will help KULR keep trading on its current exchange, but some investors are seeing negative signs in the move. 10 stocks we like better than KULR Technology Group › KULR Technology (NYSEMKT: KULR) stock is getting hit with huge selling action in Monday's trading. The company's share price was down 21.3% as of 3 p.m. ET, despite the S&P 500 (SNPINDEX: ^GSPC) being up 0.9% at the same point in the day's trading. KULR is seeing a big valuation pullback today following news that the company will carry out a reverse stock split. The new structure for the stock won't do anything to alter the fundamentals of the business, but investors are dumping shares ahead of the 8-for-1 reverse split that will take effect on June 23. After surging late in 2024's trading, KULR stock has seen big sell-offs this year. The company's share price is down roughly 74.5% year to date. As a result of the big valuation pullback, KULR's share price is currently below the $1 threshold necessary to continue trading on the NYSE-American Market. By announcing the reverse stock split before its shares had been trading below the threshold for a significant amount of time, KULR may also be able to avoid new rules from the New York Stock Exchange approved earlier this year that make it more difficult to use reverse splits to remain in compliance. KULR's reverse stock split will take effect next Monday and will result in the equivalent of eight existing shares being combined into one new share. The move will have the effect of boosting the company's share price, but it won't alter the fundamentals of the business. Continuing to trade on the NYSE-American Market exchange is probably a good thing for KULR over the long term because it will continue to make the stock easily available for a wide range of investors. On the other hand, it's not hard to see why some investors are reacting negatively to the reverse stock-split news. Reverse splits often occur because a company and its stock are struggling, and they can also limit some of the potential for explosive short-term gains that some investors may be seeking with penny stocks. Before you buy stock in KULR Technology Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and KULR Technology Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why KULR Technology Stock Is Plummeting Today was originally published by The Motley Fool
Yahoo
23 minutes ago
- Yahoo
Biomea Fusion Announces Pricing of Public Offering of Securities
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea') (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.0001 per pre-funded warrant. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire eighteen months from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $1.9999. All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Biomea. The gross proceeds to Biomea from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million, excluding any exercise of the underwriters' option to purchase additional shares and/or warrants. The offering is expected to close on June 20, 2025, subject to the satisfaction of customary closing conditions. Jefferies is acting as sole book-running manager for the offering The shares of common stock, pre-funded warrants and common stock warrants and shares of common stock issuable upon the exercise of the pre-funded warrants and common stock warrants are being offered by Biomea pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267884), that was previously filed with the U.S. Securities and Exchange Commission ('SEC') on October 14, 2022 and declared effective on October 24, 2022. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on June 17, 2025 and is available for free on the SEC's website located at The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available for free on the SEC's website located at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@ or by accessing the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. Visit us at and follow us on LinkedIn, X and Facebook. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Biomea's beliefs and expectations regarding the anticipated public offering; uncertainties related to market conditions and statements regarding timing, size and expected proceeds of the proposed offering, and Biomea's research, development and regulatory plans, the progress of ongoing and upcoming clinical trials and the timing of such events. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to completion of the public offering on the anticipated terms, or at all, market conditions and statements regarding the expected gross proceeds of the offering, timing of closing of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities and Biomea's ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Biomea's most recent annual report on Form 10-K filed on March 31, 2025 and subsequent quarterly reports on Form 10-Q, filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Biomea's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. Any forward-looking statements contained in this press release represent Biomea's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Biomea explicitly disclaims any obligation to update any forward-looking statements, except as required by law. Contact:Meichiel Jennifer WeissSr. Director, Investor Relations and Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Bank of America is bullish on these 4 under-the-radar AI stocks
Bank of America sees additional AI investing opportunities in small and mid-cap stocks. AI mentions on earnings calls have increased, especially among Russell 2000 companies. The bank shared four buy-rated AI stock picks that go beyond the Magnificent Seven. The Magnificent Seven and the AI trade have become synonymous, but there are opportunities for investors to get exposure to the AI mega-trend outside of the biggest names in the market. Small and mid-cap companies are adopting AI technology to drive earnings growth, according to Bank of America analysts. As the AI trade progresses, the next wave of beneficiaries will be companies that adopt AI into their product offerings and revenue models. While AI infrastructure companies like Nvidia benefit from size and scale, more small-cap companies are participating in the next leg of the AI trade. Jill Carey Hall, equity and quant strategist at Bank of America, wrote in a recent report that earnings calls of Russell 2000 companies have mentioned AI more frequently over the last few quarters. Software companies are particularly well-positioned to take advantage of the nascent trend of agentic AI, or AI systems that operate autonomously with limited human supervision, according to the bank. Senior technology research analyst Brad Sills reported increased signs of "green shoots" in the development of agentic application adoption at the bank's Global Technology Conference earlier this month. Examples include increased database activity to handle running AI applications and more AI-focused code. Small-cap companies in particular present AI opportunity for active stock pickers. While the overall category has lagged behind its large-cap counterpart, the current backdrop allows investors to buy up promising high-growth companies at a discounted price. Additionally, Hall sees the potential for easing inflation and a pick-up in M&A transaction volume to provide a boost to small-cap technology valuations. Below are Bank of America's four top buy-rated small and mid-cap AI picks, along with their 12-month price targets and relevant analyst commentary. Datadog Ticker: DDOG Market cap: $42.1 billion Price target: $138 Company description: Datadog provides cloud-based tools that help tech teams monitor application performance and infrastructure in real time. BofA commentary: "We believe Datadog is a share gainer in the generative AI theme, as AI-native companies are already driving 8.5% of its annual recurring revenue (ARR). As more AI-native companies scale, and non-AI native organizations release their own AI experiences, we believe Datadog stands to benefit. We believe Datadog has the potential to deliver durable 20%+ revenue growth and attractive 20%+ free cash flow margins over the coming year." Seagate Technology Ticker: STX Market cap: $27.8 billion Price target: $135 Company description: Seagate designs and manufactures data storage products, including hard drives and SSDs, for consumer and enterprise use. BofA commentary: "Seagate's HAMR ramp has begun after announcing the 2nd & 3rd hyperscaler qualifications at the May 2025 Analyst Day (1st qual. was December 2024). The company has already achieved record margins coming out of the 2023 HDD downcycle and we believe the HAMR ramp in C2H25 will propel margins higher." Kyndryl Holdings Ticker: KD Market cap: $9.3 billion Price target: $44 Company description: Kyndryl, spun off from IBM, is an IT services company that provides infrastructure services including cloud, data center, and network modernization to enterprises around the world. BofA commentary: "We continue to view Artificial Intelligence (AI)/Generative AI (GenAI) as a net tailwind for the [IT services industry] … Recent large deal signings at attractive high-single-digit pre-tax-income margins provide incremental visibility into out-year earnings power." JFrog Ticker: FROG Market cap: $4.8 billion Price target: $48 Company description: JFrog offers a DevOps platform known for its artifact repository manager, Artifactory, which streamlines software development by enabling continuous integration and delivery across the software release lifecycle. BofA commentary: "Increasing binaries from AI-related packages (Docker, Hugging Face, Python, etc.) are driving increasing usage of the platform. We think that it should benefit from increased usage as generative AI likely catalyzes the pace of software development over the medium-term." Read the original article on Business Insider Sign in to access your portfolio
